Afimmune
Dublin, IE · 1 known investors
Afimmune develops new medicines for rare and inflammatory diseases through drug discovery and development programs at various clinical and pre-clinical stages.
Investors · 1
Competitors · 2
by search overlap
Infinimmune3 shared keywordsInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
Inimmune3 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
Companies competing with Afimmune for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Afimmune do?
- Afimmune develops new medicines for rare and inflammatory diseases through drug discovery and development programs at various clinical and pre-clinical stages.
- Who are Afimmune's investors?
- Afimmune's investors include Pathway to Cures.
- Where is Afimmune headquartered?
- Afimmune is headquartered in Dublin, IE.